| |
Men
b
|
Women
b
|
SLE men/SLE women
|
---|
SNP
c
|
Gene locus
|
SLE
|
Control
|
OR (95% CI)
|
P-value
|
SLE
|
Control
|
OR (95% CI)
|
P-value
|
OR (95% CI)
d
|
P-value
|
---|
rs2476601
|
PTPN22
|
0.114
|
0.070
|
1.70 (1.09 to 2.64)
|
0.017
|
0.097
|
0.076
|
1.31 (1.08 to 1.60)
|
7.2 × 10−3
|
1.19 (0.80 to 1.77)
|
0.4
|
rs1801274
|
FCGR2A
|
0.493
|
0.474
|
1.08 (0.82 to 1.41)
|
0.6
|
0.511
|
0.474
|
1.15 (1.03 to 1.29)
|
0.011
|
0.93 (0.72 to 1.20)
|
0.6
|
rs2205960
|
TNFSF4
|
0.257
|
0.209
|
1.31 (0.96 to 1.79)
|
0.09
|
0.264
|
0.220
|
1.27 (1.12 to 1.45)
|
3.1 × 10−4
|
0.97 (0.72 to 1.29)
|
0.8
|
rs7574865
|
STAT4
|
0.306
|
0.209
|
1.67 (1.24 to 2.25)
|
7.1 × 10−4
|
0.325
|
0.243
|
1.49 (1.32 to 1.69)
|
2.8 × 10−10
|
0.92 (0.70 to 1.20)
|
0.5
|
rs6445975
|
PXK
|
0.311
|
0.241
|
1.42 (1.06 to 1.91)
|
0.018
|
0.264
|
0.226
|
1.23 (1.08 to 1.40)
|
2.2 × 10−3
|
1.26 (0.96 to 1.66)
|
0.09
|
rs17266594
|
BANK1
e
|
0.730
|
0.715
|
1.07 (0.80 to 1.45)
|
0.6
|
0.751
|
0.708
|
1.24 (1.09 to 1.41)
|
7.5 × 10−4
|
0.89 (0.67 to 1.19)
|
0.4
|
rs3131379
|
MSH5 (HLA)
|
0.132
|
0.071
|
1.98 (1.30 to 3.02)
|
1.2 × 10−3
|
0.146
|
0.072
|
2.20 (1.82 to 2.66)
|
9.6 × 10−17
|
0.89 (0.62 to 1.29)
|
0.5
|
rs729302
|
IRF5
|
0.711
|
0.689
|
1.11 (0.83 to 1.49)
|
0.5
|
0.748
|
0.691
|
1.33 (1.17 to 1.50)
|
1.0 × 10−5
|
0.83 (0.63 to 1.10)
|
0.2
|
rs10488631
|
IRF5
e
|
0.184
|
0.111
|
1.81 (1.26 to 2.61)
|
1.2 × 10−3
|
0.183
|
0.097
|
2.09 (1.76 to 2.48)
|
1.0 × 10−17
|
1.01 (0.73 to 1.40)
|
0.96
|
rs10954213
|
IRF5
|
0.639
|
0.638
|
1.01 (0.76 to 1.33)
|
0.97
|
0.685
|
0.643
|
1.21 (1.07 to 1.36)
|
1.9 × 10−3
|
0.82 (0.63 to 1.06)
|
0.13
|
rs13277113
|
C8orf13-BLK
|
0.274
|
0.250
|
1.13 (0.84 to 1.53)
|
0.4
|
0.311
|
0.245
|
1.39 (1.23 to 1.58)
|
2.8 × 10−7
|
0.84 (0.63 to 1.11)
|
0.2
|
rs4963128
|
KIAA1542
|
0.715
|
0.645
|
1.38 (1.03 to 1.85)
|
0.03
|
0.696
|
0.662
|
1.17 (1.04 to 1.32)
|
0.010
|
1.10 (0.83 to 1.45)
|
0.5
|
rs1143679
|
ITGAM
|
0.299
|
0.169
|
2.10 (1.54 to 2.85)
|
1.6 × 10−6
|
0.230
|
0.153
|
1.65 (1.42 to 1.90)
|
1.2 × 10−11
|
1.43 (1.08 to 1.88)
|
0.011
|
rs2304256
|
TYK2
|
0.735
|
0.723
|
1.06 (0.79 to 1.44)
|
0.7
|
0.770
|
0.727
|
1.26 (1.11 to 1.43)
|
4.8 × 10−4
|
0.83 (0.62 to 1.11)
|
0.2
|
rs5754217
|
UBE2L3
|
0.244
|
0.209
|
1.22 (0.89 to 1.67)
|
0.2
|
0.254
|
0.218
|
1.22 (1.07 to 1.39)
|
2.8 × 10−3
|
0.95 (0.71 to 1.27)
|
0.7
|
rs2230926
|
TNFAIP3
|
0.070
|
0.039
|
1.87 (1.07 to 3.27)
|
0.026
|
0.074
|
0.041
|
1.87 (1.45 to 2.40)
|
7.0 × 10−7
|
0.95 (0.58 to 1.55)
|
0.8
|
rs573775
|
ATG5
|
0.256
|
0.263
|
0.96 (0.71 to 1.30)
|
0.8
|
0.301
|
0.269
|
1.17 (1.04 to 1.33)
|
0.012
|
0.80 (0.60 to 1.06)
|
0.12
|
rs2187668
|
HLA-DQA1
|
0.184
|
0.107
|
1.87 (1.30 to 2.69)
|
6.0 × 10−4
|
0.201
|
0.105
|
2.15 (1.82 to 2.52)
|
7.4 × 10−21
|
0.89 (0.65 to 1.23)
|
0.5
|
rs10798269
|
1q25.1
|
0.733
|
0.656
|
1.20 (0.89 to 1.62)
|
0.2
|
0.729
|
0.680
|
1.26 (1.12 to 1.43)
|
1.7 × 10−4
|
1.02 (0.77 to 1.36)
|
0.9
|
-
aSLE, Systemic lupus erythematosus; SNP, Single-nucleotide polymorphism. bSLE men = 136; control men = 540; SLE women = 1,321; Control women = 1,188. cThe 13 first loci are the same as those studied by Hughes et al. [9]. dOR > 1.0 indicates higher frequency of the risk allele in men than in women. e
r2 = 0.94 with rs10516487 used for BANK1 and r2 = 0.94 for rs2070197 used for IRF5
[9].